HENDERSON, Nev., Jan. 30,
2025 /PRNewswire/ -- VolitionRx Limited (NYSE
AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company,
today announced the results of a large-scale study which shows that
its Nu.Q®NETs H3.1 biomarker is an independent predictor of 28-day
mortality and need for renal replacement therapy (RRT) in sepsis
and septic shock patients.
Findings published in the paper currently undergoing peer review
and accessible on MEDRXIV, demonstrate Nu.Q® NETs H3.1 is a
promising novel biomarker for early mortality and organ dysfunction
in sepsis, with significantly higher levels found in septic shock
than sepsis patients and a clear dose-response relationship with
acute kidney injury severity. The findings indicate Nu.Q® NETs
H3.1's potential clinical utility for risk stratification and early
intervention in critically ill patients presenting with sepsis.
The study is a secondary analysis of circulating H3.1
nucleosomes in plasma samples collected from 971 patients with
sepsis and septic shock who participated in the multicentre,
randomised, bifactorial, prospective SISPCT trial
(Clinicaltrials.gov identifier, NCT00832039).
Professor Michael Bauer, Chair of
the Department of Anaesthesiology and Intensive Care Medicine, Jena
University Hospital, Germany and
co-author of the paper said:
"Our study establishes H3.1 nucleosomes as a biomarker
delineating organ dysfunction in sepsis, particularly for early
mortality and RRT. The clear stratification of risk and
independence from conventional markers suggests clinical
utility.
"Being able to predict a sepsis patient's clinical course early,
by using Nu.Q® NETs in clinical practice, could significantly
enhance sepsis management, enabling physicians more time to
intervene and improve patient outcomes."
Dr Andrew Retter, Chief Medical
Officer at Volition said:
"We are excited to report the findings of this large-scale
independent clinical study, the culmination of many years
work. Nu.Q® NETs, Volition's nucleosome quantification
technology, is a simple, low-cost, accessible test to detect
diseases associated with NETosis. Although NETs play a critical
role in our normal immune response, elevated levels of NETs can
lead to tissue damage and in severe cases, sepsis, organ failure,
and death. These findings advance our understanding of nucleosome
biology in critical illness and help inform future therapeutic
strategies.
Introducing Nu.Q® NETs into hospitals could lead to new ways of
treating sepsis, improve patient survival and the quality of life
of survivors."
Volition is currently advancing several active commercial
discussions with significant players in the diagnostic space,
including large markets such as sepsis; the findings from the
latest study support this ongoing licensing process. Volition is
developing simple, easy-to-use, cost-effective blood tests to help
diagnose and monitor a range of life-altering diseases in both
humans and animals.
For more information about Volition's technology go to:
www.volition.com
About Volition
Volition is a multi-national company focused on advancing the
science of epigenetics. Volition is dedicated to saving lives and
improving outcomes for people and animals with life-altering
diseases through earlier detection, as well as disease and
treatment monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential not only to prolong the
life of patients but also improve their quality of life.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. Such website address is
included in this document as an inactive textual reference
only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, Volition's expectations related to revenue
opportunities and growth, the timing, completion, success and
delivery of data from clinical studies, the timing of publications,
, the effectiveness and availability of Volition's blood-based
diagnostic, prognostic and disease monitoring tests, Volition's
ability to develop and successfully commercialize such test
platforms for early detection of cancer and other diseases as well
as serving as a diagnostic, prognostic or disease monitoring tools
for such diseases, and Volition's success in securing licensing
and/or distribution agreements with third parties for its products.
Volition's actual results may differ materially from those
indicated in these forward-looking statements due to numerous risks
and uncertainties, including, without limitation, results of
studies testing the efficacy of its tests. For instance, if
Volition fails to develop and commercialize diagnostic, prognostic
or disease monitoring products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products; a failure by
the marketplace to accept the products in Volition's development
pipeline or any other diagnostic, prognostic or disease monitoring
products Volition might develop; Volition's failure to secure
adequate intellectual property protection; Volition will face
fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
and disease monitoring market and its rapid technological change;
downturns in domestic and foreign economies; and other risks,
including those identified in Volition's most recent Annual Report
on Form 10-K and Quarterly Reports on Form 10-Q, as well as other
documents that Volition files with the Securities and Exchange
Commission. These statements are based on current expectations,
estimates and projections about Volition's business based, in part,
on assumptions made by management. These statements are not
guarantees of future performance and involve risks, uncertainties
and assumptions that are difficult to predict. Forward-looking
statements are made as of the date of this press release, and,
except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos
are trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
View original
content:https://www.prnewswire.com/news-releases/large-clinical-study-establishes-nuq-nets-h3-1-as-an-independent-predictor-of-28-day-mortality-in-sepsis-302364314.html
SOURCE VolitionRx Limited
